Current Footprint - Bioflux®
Portfolio of complementary technologies:
- Biotres ® - FDA cleared
- Bioheart ® - consumer product currently in initial production
- Biocare® App – about to go through field testing
- Bioflux® 2 – in alpha prototyping
Large Scale production in place.
Medicare Reimbursement in place.
Cardiologists across 29 states use the Bioflux daily.
Currently have over 500 centers across 29 states: focused on expanding salesforce to expand footprint.
Our sales force is comprised of seasoned professionals, each with a proven track record of introducing disruptive cardiovascular technologies to the marketplace.
Use a proprietary data tool to identify target markets within the US, based on CMS reimbursement data.
More Key Details From The Company Presentation.
And as I mentioned above, BTCY has 5 potential catalysts that could provide it with a breakout spark. Here they are:
No. 1 BTCY Potential Catalyst - Zacks Small-Cap Research Provides $7.50 Price Target
In 2022, BTCY was tagged with a strong target from Zacks Small-Cap Research that is providing this profile with over 400% potential upside from Thursday's closing valuation.
Here's some key details from the report:
We are optimistic about the outlook for BTCY’s technology and ecosystem as the company expands both distribution and its product and service offerings. At this early stage in its development, it is difficult to compare BTCY to other companies on traditional valuation metrics such as P/E or EV/ EBITDA, in our view. We therefore value BTCY shares using a peer comparables valuation methodology based on EV/Sales.
We appreciate the company’s runway and addressable market for additional penetration of its network for Bioflux, the Biotres launch contribution and the recurring revenues stream and shift in the sales mix towards higher margin TaaS over time. We therefore think the current share price level does not reflect the fundamental value of the company’s prospects. As the company continues to advance its strategy, we would anticipate multiple and share price expansion. We believe accelerating revenue ramp as both Bioflux and Biotres gain traction could be catalysts.
Although the revenue arc for BTCY is somewhat unclear at this stage because of many variables, including whether the pandemic has a lingering impact and global logistics challenges, we believe it reasonable to project that BTCY can attain revenue in the $40-$45Mn range by FY25-FY26. We reach $7.50 valuation per share based on peer group median of 9.0x EV/sales applied to this anticipated range, which includes a ramp-up in contribution from Biotres, Bioflux and other offerings in development.
No. 2 BTCY Potential Catalyst - Company Announces U.S. Launch Of Biocare Cardiac
Biotricity Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics
REDWOOD CITY, CA / ACCESSWIRE / October 26, 2022 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the U.S. launch of Biocare Cardiac. The national roll-out follows two successful pilot programs in Oklahoma City with CardioVascular Health Clinic, a medical facility providing high-quality cardiovascular care to more than 40,000 patients, and a four-month pilot with Lexington Heart Specialists in Kentucky, a medical practice providing high-quality cardiovascular care to more than 20,000 patients.
Marcus Smith, M.D., one of the pilot project leaders at CardioVascular Health Clinic, commented, "CV Health integrated the Biocare Cardiac platform as part of our commitment to continued, ongoing care for patients. This platform technology integrates with diagnostic devices and telemedicine providing peace of mind for the patient. Importantly, it engaged patients, while providing bi-directional communication and ongoing monthly reporting that allows our practice to identify those who may need additional care, leading to better outcomes."
Dr. Hal Skinner, of Lexington Heart Specialists, spoke about the benefits for his patients after enrollment in the program, "We had patients driving hours for appointments with our doctors. The ability to enroll these patients in the Biocare Cardiac platform and monitor them with Bioheart and Biokit has changed dramatically how we manage their health. This improves their quality of life and gives everyone caring for them peace of mind. If we see something concerning a patient report, we immediately request that a patient come in for further assessment. We have already changed medications and adjusted treatment management after reviewing patients' data."
Read the full article here.
No. 3 BTCY Potential Catalyst - Achieving A Huge Milestone (2Bn Analyzed Heartbeats)
Biotricity Surpasses 2Bn Recorded and Analyzed Heartbeats for Atrial Fibrillation (AFib)
REDWOOD CITY, CA / ACCESSWIRE / October 4, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2Bn heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke.
Bioflux®, Biotricity's high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient's ECG information, has captured billions of heartbeats to date, monitored in real-time by Bioflux's built in algorithms, certified cardiac technicians and benchmarked by Artificial Intelligence (AI). Leveraging the Company's proprietary AI, over 2Bn of the total heartbeats to date have been segmented for AFib analysis. According to Emergen Research, the global recurrent market for AFib is expected to reach $26Bn by 2027, growing at a CAGR of 13.2%.
This large data set provides further benefits for patients, providers and ultimately clinical research for the future of predictive monitoring. Additionally, it allows Biotricity to scale faster and operate more efficiently, develop better automation, yielding growth and better margins in the future. The consistent focus on R&D and data capture has positioned Biotricity with a significant competitive advantage in key cardiac segments of the market, such as AFib.
Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "AFib unfortunately continues to be a leading cardiac risk globally, growing annually at alarming rates. We have purposely designed our ecosystem to monitor the patient 24/7 while leveraging our innovative technology that uniquely combines AI with data and predictive capabilities. In doing so, we can create better and faster analytics for preventative patient monitoring and lifestyle management. For AFib specifically, the ability to significantly narrow the time of diagnosis reduces risk for the patient and liability for the provider, giving our technology the ability to positively impact millions who suffer with AFib globally. Additionally, as we continue to collect more data through our R&D efforts, our internal quality review process will scale and further increase in efficiency, allowing us to continue to grow our margins."
Read the full article here.
No. 4 BTCY Potential Catalyst - Company Earns NIH Grant And Will Carry Out Phase I Study Of Bioflux-AI
Biotricity Wi-ns NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled Real-Time Monitoring and Predictive Analytics for Stroke due to Chronic Kidney Failure
REDWOOD CITY, CA / ACCESSWIRE / September 7, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity's innovative artificial intelligence-driven (‘AI') system of real-time monitoring and prediction technology, in subjects with Chronic Kidney Disease (‘CKD').
Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "We are pleased to be working on this critically important project with the NIH, further validating our current artificial intelligence technology and entering into a new disease profile for us in CKD. The real-time monitoring of stroke risk in CKD patients, and in particular for those undergoing dialysis, is likely to influence adopted therapeutic strategies and promote a more personalized therapeutic approach. Better care and prevention through monitoring of these high-risk patients is expected to reduce mortality rates and the high per-capita cost of treatment, which is currently five-times higher than the average healthcare spend. The completion of this feasibility study will pave the road for further development and optimization of the AI-based algorithm for stroke prediction in CKD patients. This will widen the application to a larger patient demographic, thereby validating the predictive algorithm for the potential benefit of patients with other chronic diseases."
Biotricity is developing Bioflux-AI, an innovative system for real-time monitoring and prediction of stroke episodes in CKD patients. Bioflux-AI combines an FDA-approved, high-precision, small mobile cardiac telemetry (MCT) device with AI-driven algorithms specifically trained for the prediction of stroke in stage 4 and stage 5 CKD patients. Biotricity has previously generated and validated algorithms for the automated detection of ECG abnormalities, including Atrial Fibrillation (AF).
Read the full article here.
No. 5 BTCY Potential Catalyst - Added Exposure From Joining The Russell Microcap Index
Biotricity to Join Russell Microcap(R) Index
REDWOOD CITY, CA / ACCESSWIRE / June 23, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that the Company is expected to join the Russell Microcap® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022.
Membership in the Russell Microcap® Index, which remains in place for one year, includes inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12Tn in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
Read the full article here.
BTCY Recap - The 5 Top Potential Breakout Catalysts To Know
No. 1 - Zacks Small-Cap Research Provides $7.50 Price Target
No. 2 - Company Announces U.S. Launch Of Biocare Cardiac
No. 3 - Achieving A Huge Milestone (2Bn Analyzed Heartbeats)
No. 4 - Company Earns NIH Grant And Will Carry Out Phase I Study Of Bioflux-AI
No. 5 - Added Exposure From Joining The Russell Microcap Index
Coverage is officially initiated on BTCY. When time permits, do this: